Patients treated by tegaserod for irritable bowel syndrome with constipation showed significant improvement in fibromyalgia symptoms. A pilot study |
| |
| Authors: | Tatiana Reitblat Doron Zamir Ilia Polishchuck Galina Novochatko Stephen Malnick Leonid Kalichman |
| |
| Institution: | (1) Rheumatology Unit, Barzilai Medical Center, Ashkelon, Israel;(2) Internal Medicine Department “D”, Barzilai Medical Center, Ashkelon, Israel;(3) Gastroenterology Unit, Barzilai Medical Center, Ashkelon, Israel;(4) Institute of Gastrointestinal and Liver Diseases and Medicine Department C, Kaplan Hospital, Rehovot, Israel;(5) Department of Physical Therapy, Recanati School for Community Health Professions, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; |
| |
| Abstract: | The symptoms of irritable bowel syndrome (IBS) are commonly seen in fibromyalgia (FM) patients. This study aimed to evaluate
the effect of 5-hydroxytryptamin-4 receptor partial agonist (tegaserod) on the symptoms of FM among the patients who receive
the medicine because of IBS. Forty-one female patients with IBS and constipation, which were subjects to tegaserod treatment,
were examined by rheumatologist and 14 were found to suffer from FM. The fibromyalgia impact questionnaire (FIQ) and clinical
examination were done before tegaserod treatment and 1 month after. The IBS status, the total FIQ score, the number of tender
points and pain in tender points were lowered significantly after the treatment (p < 0.001 for all variables). The results of this pilot study provide the preliminary evidence that FM patients can benefit
from treatment by 5-hydroxytryptamin-4 receptor partial agonist. Additional studies are needed to support this conclusion. |
| |
| Keywords: | Comorbidity Fibromyalgia Irritable bowel syndrome Tegaserod |
| 本文献已被 SpringerLink 等数据库收录！ |
|
